AU2001295601A1 - N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists - Google Patents

N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists

Info

Publication number
AU2001295601A1
AU2001295601A1 AU2001295601A AU9560101A AU2001295601A1 AU 2001295601 A1 AU2001295601 A1 AU 2001295601A1 AU 2001295601 A AU2001295601 A AU 2001295601A AU 9560101 A AU9560101 A AU 9560101A AU 2001295601 A1 AU2001295601 A1 AU 2001295601A1
Authority
AU
Australia
Prior art keywords
sub
sup
alkyl
img
character
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295601A
Inventor
Gurdip Bhalay
Trevor John Howe
Darren Mark Le Grand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0024675A external-priority patent/GB0024675D0/en
Priority claimed from GB0120549A external-priority patent/GB0120549D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2001295601A1 publication Critical patent/AU2001295601A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

Compounds of formula (I) in free or salt form, where Ar<SUP>1 </SUP>is phenyl substituted by one or more substituents selected from halogen, cyano, nitro, and C<SUB>1</SUB>-C<SUB>8</SUB>-alkyl optionally substituted by cyano or halogen, Ar<SUP>2 </SUP>is phenyl optionally which is unsubstituted or substituted by one or more substituents selected from halogen, cyano, hydroxy, nitro, C<SUB>1</SUB>-C<SUB>8</SUB>-alkyl, C<SUB>1</SUB>-C<SUB>8</SUB>-haloalkyl, C<SUB>1</SUB>-C<SUB>8</SUB>-alkoxy or C<SUB>1</SUB>-C<SUB>8</SUB>-alkoxycarbonyl, R<SUP>1 </SUP>is C<SUB>1</SUB>-C<SUB>8</SUB>-alkyl substituted by hydroxy, C<SUB>1</SUB>-C<SUB>8</SUB>-alkoxy, acyloxy, -N(R<SUP>2</SUP>)R<SUP>3</SUP>, halogen, carboxy, C<SUB>1</SUB>-C<SUB>8</SUB>-alkoxycarbonyl, phenyl-C<SUB>1</SUB>-C<SUB>8</SUB>-alkoxycarbonyl, -CON(R<SUP>4</SUP>)R<SUP>5 </SUP>or by a monovalent cyclic organic group, R<SUP>2 </SUP>and R?3 <img id="CUSTOM-CHARACTER-00001" he="2.12mm" wi="1.44mm" file="US07034042-20060425-P00001.TIF" alt="custom character" img-content="character" img-format="tif"/> are each independently hydrogen or C<SUB>1</SUB>-C<SUB>8</SUB>-alkyl, or R<SUP>2 </SUP>is hydrogen and R<SUP>3 </SUP>is acyl or SO<SUB>2</SUB>R<SUP>6</SUP>, or R<SUP>2 </SUP>and R<SUP>3 </SUP>together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, R<SUP>4 </SUP>and R<SUP>5 </SUP>are each independently hydrogen, C<SUB>1</SUB>-C<SUB>8</SUB>-alkyl optionally substituted by hydroxy or phenyl, or phenyl optionally substituted by C<SUB>1</SUB>-C<SUB>8</SUB>-alkyl, halogen, cyano or C<SUB>1</SUB>-C<SUB>8</SUB>-alkoxy, or R<SUP>4 </SUP>and R<SUP>5 </SUP>together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, R?6 <img id="CUSTOM-CHARACTER-00002" he="2.12mm" wi="1.44mm" file="US07034042-20060425-P00002.TIF" alt="custom character" img-content="character" img-format="tif"/> is C<SUB>1</SUB>-C<SUB>8</SUB>-alkyl, C<SUB>1</SUB>-C<SUB>8</SUB>-haloalkyl, or phenyl optionally substituted by C<SUB>1</SUB>-C<SUB>8</SUB>-alkyl, and n is 1, 2, 3 or 4. The compounds are useful as pharmaceuticals.
AU2001295601A 2000-10-09 2001-10-08 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists Abandoned AU2001295601A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0024675 2000-10-09
GB0024675A GB0024675D0 (en) 2000-10-09 2000-10-09 Organic compounds
GB0120549 2001-08-23
GB0120549A GB0120549D0 (en) 2001-08-23 2001-08-23 Organic compounds
PCT/EP2001/011627 WO2002030898A1 (en) 2000-10-09 2001-10-08 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists

Publications (1)

Publication Number Publication Date
AU2001295601A1 true AU2001295601A1 (en) 2002-04-22

Family

ID=26245127

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001295601A Abandoned AU2001295601A1 (en) 2000-10-09 2001-10-08 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists

Country Status (12)

Country Link
US (1) US7034042B2 (en)
EP (1) EP1330436B1 (en)
JP (1) JP4199539B2 (en)
CN (1) CN1209351C (en)
AT (1) ATE472533T1 (en)
AU (1) AU2001295601A1 (en)
BR (1) BR0114485A (en)
CA (1) CA2423296C (en)
DE (1) DE60142484D1 (en)
ES (1) ES2348290T3 (en)
PT (1) PT1330436E (en)
WO (1) WO2002030898A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117387D0 (en) * 2001-07-17 2001-09-05 Novartis Ag Organic compounds
EP1505067A4 (en) * 2002-04-25 2006-06-21 Teijin Ltd 4,4-disubstituted piperidine derivatives having ccr3 antagonism
CN101312965B (en) * 2005-11-24 2011-07-20 卫材R&D管理有限公司 Morpholine type cinnamide compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673684A (en) * 1984-04-04 1987-06-16 Terumo Corporation Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
JPH0660160B2 (en) * 1985-12-13 1994-08-10 テルモ株式会社 Amide derivative and antiallergic agent containing the same
JPS63139124A (en) * 1986-12-01 1988-06-10 Terumo Corp Remedy for nephritis
JPS63179869A (en) * 1987-01-20 1988-07-23 Dainippon Pharmaceut Co Ltd Piperidine derivative
DE19756235A1 (en) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab New piperidinyl-substituted pyridylalkane alkene and alkane carboxylic acid amides
CA2361366A1 (en) 1999-03-26 2000-10-05 Nicholas Kindon Novel compounds
TWI227231B (en) * 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3

Also Published As

Publication number Publication date
ES2348290T3 (en) 2010-12-02
BR0114485A (en) 2003-11-18
ATE472533T1 (en) 2010-07-15
JP4199539B2 (en) 2008-12-17
US20040087621A1 (en) 2004-05-06
CN1209351C (en) 2005-07-06
CN1468222A (en) 2004-01-14
WO2002030898A1 (en) 2002-04-18
DE60142484D1 (en) 2010-08-12
PT1330436E (en) 2010-10-11
EP1330436B1 (en) 2010-06-30
JP2004511467A (en) 2004-04-15
CA2423296C (en) 2009-12-29
EP1330436A1 (en) 2003-07-30
US7034042B2 (en) 2006-04-25
CA2423296A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
TW200716528A (en) Cyclopropanecarboxamide derivatives
HUP0401478A2 (en) Pyrazolycarboxanilides as fungicides
HUP0102360A2 (en) 1,3-oxazoline and 1,3-thiazoline derivatives, method for producing the same and their use as pesticides
MY119238A (en) 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
EP1775289A4 (en) Novel imidazolidine derivatives
MXPA02003792A (en) Pyrazole derivatives which modulate human serotonin receptors.
MY126139A (en) Piperidine compounds for use as ccr-3 inhibitors
ATE29255T1 (en) SUCCINIMID DERIVATIVES AND THEIR PREPARATION.
BRPI0506927A (en) organic compounds
PH12015501098A1 (en) Antituberculous composition comprising oxazole compounds
DE602004009200D1 (en) TETRAHYDROCHINAZOLINE DERIVATIVES AS CFR ANTAGONISTS
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
DE69401584D1 (en) BETA, BETA-DIMETHYL-4-PIPERIDINETHANAMINE DERIVATIVES AS INHIBITORS OF THE CHOLESTERIN BIOSYNTHESIS
ATE34976T1 (en) ARYLCYCLOBUTYLALKYLAMINES AND THEIR USE AS ANTIDEPRESSIVE DRUGS.
WO2002000638A3 (en) Substituted phthalides as anti-convulsive drugs
CA2302943A1 (en) Phthalazine compounds and therapeutic agents for erectile dysfunction
ES449596A1 (en) Pyrimidine derivatives
AU2001295601A1 (en) N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists
HRP20010630B1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
ATE170851T1 (en) GUANIDINOTHIAZOLE DERIVATIVES AND THEIR USE AS H2 RECEPTOR ANTAGONISTS
SE0301445D0 (en) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
ATE318265T1 (en) AMIDINE DERIVATIVES, THEIR PRODUCTION AND USE AS MEDICATIONS
HUP9701325A1 (en) New 2,3-benzodiazepine derivatives
ATE497497T1 (en) 1,2,4-TRIAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
ATE374751T1 (en) 3,4-DIHYDRO-1H-QUINOLINE-2-ONE DERIVATIVES AS NOREPINEPHRINE RUPUP INHIBITORS